Yu Jeong Il, Choi Doo Ho, Huh Seung Jae, Ahn Sung Ja, Lee Ji Shin, Shin Kyung Hwan, Kwon Youngmee, Kim Yong Bae, Suh Chang-Ok, Kim Jin Hee, Cho Jihyoung, Kim In Ah, Lee Jong Hoon, Park Won
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
Clin Breast Cancer. 2015 Apr;15(2):e105-15. doi: 10.1016/j.clbc.2014.10.002. Epub 2014 Oct 12.
This retrospective study was performed to investigate the need for management modification in MBC according to evaluation of characteristics and failure patterns compared with IDC.
We performed this multicenter study taking MBC and randomly assigned IDC cases matched for age (± 3 years), pathologic stage (T and N), locoregional treatment methods (surgery with or without radiation therapy), and period of treatment (± 6 months) that occurred from January 1999 to November 2011 in the 6 institutions of the Korean Radiation Oncology Group.
A total of 144 female MBC patients were enrolled. The median follow-up was 51 months (range, 1-186 months). The rates of positivity for estrogen receptor (P < .001), progesterone receptor (P < .001), and HER2 (P = .007) were significantly lower in MBC patients. During follow-up, recurrence developed in 22 (15.3%) MBC and 6 (4.2%) IDC patients (P = .002). The median time to recurrence of MBC and IDC was 15 months and 24 months, respectively. Most instances of recurrence in MBC developed in the triple-negative (TN) subgroup (TN-MBC). In particular, locoregional recurrence developed exclusively in the TN-MBC subgroup. In the TN-MBC subgroup, the number of risk factors (pT2-3, N1-3) was related to significant differences in overall survival (P = .001) and recurrence-free survival (P < .001).
The MBC patients had a higher rate of TN, poorer differentiation, and a higher recurrence rate than did the IDC patients. Considering the unique characteristics and failure patterns, it is necessary to modify the current management guidelines for MBC.
本回顾性研究旨在根据与浸润性导管癌(IDC)相比的特征和失败模式评估,探讨转移性乳腺癌(MBC)管理调整的必要性。
我们进行了这项多中心研究,选取了MBC患者,并随机分配了年龄(±3岁)、病理分期(T和N)、局部区域治疗方法(手术联合或不联合放射治疗)以及治疗时间(±6个月)相匹配的IDC病例,这些病例于1999年1月至2011年11月在韩国放射肿瘤学组的6家机构中出现。
共纳入144例女性MBC患者。中位随访时间为51个月(范围1 - 186个月)。MBC患者中雌激素受体阳性率(P <.001)、孕激素受体阳性率(P <.001)和HER2阳性率(P =.007)显著较低。随访期间,22例(15.3%)MBC患者和6例(4.2%)IDC患者出现复发(P =.002)。MBC和IDC的中位复发时间分别为15个月和24个月。MBC的大多数复发情况发生在三阴性(TN)亚组(TN - MBC)。特别是,局部区域复发仅在TN - MBC亚组中出现。在TN - MBC亚组中,危险因素数量(pT2 - 3,N1 - 3)与总生存期(P =.001)和无复发生存期(P <.001)的显著差异相关。
与IDC患者相比,MBC患者的TN率更高、分化更差且复发率更高。考虑到其独特的特征和失败模式,有必要修改当前MBC的管理指南。